Stockscreener 앱 받기
1.33
0.75%
-0.01
시간 외 거래:
1.42
0.09
+6.77%
전일 마감가:
$1.34
열려 있는:
$1.37
하루 거래량:
24,557
Relative Volume:
0.01
시가총액:
$5.43M
수익:
-
순이익/손실:
$-6.78M
주가수익비율:
-0.3722
EPS:
-3.5729
순현금흐름:
$-4.67M
1주 성능:
-2.92%
1개월 성능:
+16.67%
6개월 성능:
+4.72%
1년 성능:
+640.95%
1일 변동 폭
$1.30
$1.37
1주일 범위:
$1.28
$1.40
52주 변동 폭
$0.10
$6.80
Clearmind Medicine Inc Stock (CMND) Company Profile
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Clearmind Medicine files patent for PTSD treatment compounds - Investing.com
Clearmind Medicine files patent for PTSD treatment compounds - Investing.com India
SciSparc shares up on patents filed for psychedelic compounds with Clearmind - MSN
SciSparc and Clearmind Innovate Mental Health Treatment - TipRanks
Clearmind Medicine files patent for novel MDMA therapy - Investing.com
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Yahoo Finance UK
SciSparc-Clearmind Medicine Collaboration Leads to - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent ... - The Bakersfield Californian
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - StockTitan
A History of Outperforming Analyst Forecasts and Beating the Odds: Clearmind Medicine Inc (CMND) - SETE News
Financial Metrics Check: Clearmind Medicine Inc (CMND)’s Ratios for Trailing Twelve Months - The Dwinnex
Clearmind and SciSparc file patent for ketamine-based therapy - Investing.com
SciSparc and Clearmind Innovate in Mental Health Therapy - TipRanks
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment - Morningstar
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - StockTitan
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - Benzinga
CMND’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Clearmind receives patent for drug to treat binge behavior - Green Market Report
Clearmind Medicine Inc (CMND) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com India
Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Yahoo Finance
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Morningstar
Clearmind Medicine Inc (CMND) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Is CMND’s price to cash per share ratio a concern for investors? - US Post News
Financial Metrics Unveiled: Clearmind Medicine Inc (CMND)’s Key Ratios in the Spotlight - The Dwinnex
Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com
Clearmind, Yissum Apply for International Patent for Psychedelics - MarketWatch
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - StockTitan
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - Morningstar
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 0.8% - Defense World
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug - EIN News
SciSparc and Clearmind report progress in obesity treatment - Investing.com
Move over Ozempic, psychedelics might help people lose weight - Green Market Report
SciSparc’s Collaboration with Clearmind Medicine Continues - GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug - StockTitan
Clearmind gains on exclusive global rights to psychedelic compounds for PTSD treatment - MSN
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 - EIN News
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research - Morningstar
Clearmind Medicine (NASDAQ:CMND) Stock Quotes, Forecast and News Summary - Benzinga
Clearmind partners for global roll-out of alcohol substitute By Investing.com - Investing.com South Africa
Clearmind partners for global roll-out of alcohol substitute - Investing.com India
Clearmind partners for global roll-out of alcohol substitute - Investing.com
Clearmind Medicine to source manufacturers and distributors for its alcohol substitute beverage product - Seeking Alpha
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product - StockTitan
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product - Afternoon Headlines
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product - Morningstar
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 2.8% - Defense World
Clearmind Medicine Inc (CMND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.27%
자본화:
|
볼륨(24시간):